Nicox Plans Debt Repayment with NCX 470 Progress

Nicox, an international ophthalmology company listed on Euronext Growth Paris, expects to fully repay its financial debts by 2026. This projection follows positive outcomes from the second pivotal Phase 3 clinical trial for NCX 470, dubbed Denali, and its global licensing to Kowa. The company anticipates New Drug Application (NDA) submissions in the U.S. in the first half of 2026 and in China subsequently. Upon these submissions, Nicox expects to generate recurrent revenue starting in 2027, complemented by milestone payments upon NDA approval.

NCX 470's licensing deals cover global markets, allowing Kowa and Ocumension to bear the costs related to NDA submissions in the U.S. and China, respectively. Additionally, Nicox is exploring strategic options like collaborations or business combinations to strengthen its financial stance. Meanwhile, research on NCX 1728 continues under an extended agreement with Glaukos for potential glaucoma treatment. Nicox remains committed to maintaining cost control while optimizing resource allocation to sustain its strategic initiatives.